A surge in healthcare costs is straining business budgets and household finances across the country. Prescription drugs now represent more than 25 percent of employer healthcare spending, forcing companies to spend less on wages and growth investments.
Two industry groups that normally clash—The ERISA Industry Committee, which represents large employers, and the Pharmaceutical Care Management Association, which represents pharmacy benefit managers—have united behind a single target: drug manufacturers. Both say current prescription drug spending is excessive and unsustainable.
At the center of the dispute is the Hatch-Waxman Act of 1984, which granted brand-name drugs market exclusivity to recoup development costs while establishing pathways for generic competition after a set period. The law was designed as a bargain between innovation and affordability. Four decades later, drugmakers have shattered that bargain, critics say.
Manufacturers exploit patent loopholes to maintain monopolies. One tactic: securing multiple secondary patents for minor changes—altering a pill's coating or tweaking packaging—creating what industry insiders call "patent thickets." These maneuvers are not genuine innovation. They extend a brand drug's exclusivity period and block cheaper generic and biosimilar alternatives from reaching patients.
The math is stark. Generic drugs and biosimilars currently save American consumers $467 billion annually. Yet brand-name drugs make up only 10 percent of all prescriptions filled but command 88 percent of total drug spending. Legal maneuvering by manufacturers frequently prevents less expensive options from reaching the market even when an expensive brand-name drug should face generic competition.
Earlier this year, Congress passed sweeping regulations targeting prescription benefit managers, banning specific business practices and mandating full transparency on claims, drugs, contracts and fees. With PBMs now under closer scrutiny, lawmakers are turning their attention upstream—to the manufacturers themselves.
Policymakers now face a central question: how to balance rewarding pharmaceutical investment with keeping drugs affordable. The current system, as critics argue, forces people to sacrifice health and financial security to bolster brand drugmaker profits.
